Roche(US:RHHBY) Xin Jing Bao·2025-11-01 09:03Core Insights - Roche will showcase over 40 products and innovative solutions at the upcoming China International Import Expo, marking its eighth consecutive participation [1][2] - The company will present more than ten products set to launch in China, covering major diseases such as Alzheimer's, Parkinson's, hypertension, and metabolic diseases [2] - Roche is investing 2.04 billion yuan in a new biopharmaceutical production base in Shanghai, which will focus on local production of its innovative ophthalmic drug, Lucentis [1][2] Company Strategy - Roche's participation in the Import Expo serves as a strategic platform for deepening dialogue with the government and partners, facilitating the transformation of global innovative drugs into marketable products in China [2] - The new production base in Shanghai is a key milestone in Roche's localization strategy, being the first facility in China to produce large molecule biopharmaceuticals locally [2] - The continuous improvement of China's business environment and innovation ecosystem is seen as a fertile ground for foreign enterprises like Roche to thrive [2]